IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.071
AS - Asia 2.218
EU - Europa 1.337
SA - Sud America 361
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 16.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.012
SG - Singapore 1.288
CN - Cina 329
HK - Hong Kong 316
IT - Italia 309
BR - Brasile 301
IE - Irlanda 232
DE - Germania 190
RU - Federazione Russa 129
GB - Regno Unito 93
UA - Ucraina 72
VN - Vietnam 64
FI - Finlandia 61
FR - Francia 61
IN - India 48
NL - Olanda 38
SE - Svezia 35
CA - Canada 34
KR - Corea 32
ID - Indonesia 31
AT - Austria 26
PL - Polonia 26
AR - Argentina 23
ES - Italia 23
JP - Giappone 22
MX - Messico 16
TR - Turchia 16
CO - Colombia 13
ZA - Sudafrica 13
PK - Pakistan 12
CH - Svizzera 9
CL - Cile 7
EC - Ecuador 7
IQ - Iraq 7
MY - Malesia 7
PY - Paraguay 7
BE - Belgio 6
MA - Marocco 6
BD - Bangladesh 5
IR - Iran 5
KG - Kirghizistan 5
LT - Lituania 5
RO - Romania 5
AU - Australia 4
DZ - Algeria 4
JM - Giamaica 4
PH - Filippine 4
PT - Portogallo 4
TW - Taiwan 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
EU - Europa 3
GR - Grecia 3
KE - Kenya 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
EG - Egitto 2
ET - Etiopia 2
GE - Georgia 2
JO - Giordania 2
KZ - Kazakistan 2
MN - Mongolia 2
NP - Nepal 2
SI - Slovenia 2
TN - Tunisia 2
VE - Venezuela 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
CG - Congo 1
DK - Danimarca 1
HN - Honduras 1
IL - Israele 1
NO - Norvegia 1
SA - Arabia Saudita 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 16.031
Salva come PNG Salva come JPEG
Città #
Wilmington 3.182
Houston 2.940
Woodbridge 1.607
Fairfield 687
Singapore 571
Ashburn 503
Seattle 331
Hong Kong 315
Chandler 302
Cambridge 255
Dublin 213
Ann Arbor 191
Dallas 171
Medford 151
Beijing 149
The Dalles 110
Santa Clara 107
Dearborn 93
Rome 76
Lawrence 72
Los Angeles 70
Council Bluffs 65
Munich 65
San Diego 54
Buffalo 46
Jacksonville 43
New York 42
Redondo Beach 36
Nuremberg 31
Jakarta 30
Moscow 30
London 28
São Paulo 26
Lappeenranta 24
Milan 23
Del Norte 21
Hanoi 21
Zhengzhou 21
Seoul 19
Ho Chi Minh City 18
Menlo Park 18
Perugia 16
Boardman 15
Chennai 15
Helsinki 15
Redwood City 15
Salt Lake City 15
Brooklyn 14
Toronto 14
Boston 13
Esslingen am Neckar 13
Kraków 13
Chicago 12
Hyderabad 12
Shanghai 12
Tokyo 12
Vienna 12
Atlanta 11
Colorado Springs 11
Warsaw 11
Denver 10
Falls Church 10
Guangzhou 10
Johannesburg 9
Montreal 9
Pune 9
Saint Petersburg 9
Turku 9
Ankara 8
Engelhard 7
Frankfurt am Main 7
Phoenix 7
Poplar 7
Porto Alegre 7
San Francisco 7
San Jose 7
Asunción 6
Brussels 6
Columbus 6
Goiânia 6
Guiyang 6
Kilburn 6
Mexico City 6
Norwalk 6
Orem 6
Rio de Janeiro 6
Stockholm 6
Turin 6
Amsterdam 5
Belo Horizonte 5
Dongguan 5
Lahore 5
Mountain View 5
Nanchang 5
Nanjing 5
Putrajaya 5
Bari 4
Bogotá 4
Bologna 4
Brasília 4
Totale 13.268
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 506
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 422
Tildrakizumab for treating psoriasis 414
Brodalumab for the treatment of psoriasis 410
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 410
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 390
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 389
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 386
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 380
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 380
Tofacitinib for the treatment of psoriasis 374
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 358
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 358
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 356
A safety evaluation of guselkumab for the treatment of psoriasis 340
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 330
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 320
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 319
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 318
Photo-recall cutaneous reaction to gemcitabine 298
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 296
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 294
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 291
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 281
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 279
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 259
Pharmacotherapeutic management of psoriasis in adolescents and children 258
Skin immunity and its dysregulation in psoriasis 244
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 241
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 239
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 235
Successful treatment of psoriatic crumbly nails with ustekinumab 233
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 230
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 210
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 206
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 190
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 184
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 182
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 179
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 172
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 131
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 124
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 122
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 116
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 114
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 108
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 102
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 101
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 96
Italian guidelines in diagnosis and treatment of alopecia areata 95
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 94
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 87
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 87
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 84
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 83
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 82
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 79
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 74
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 74
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 71
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 70
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 70
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 70
Linear psoriasis following the typical distribution of the sciatic nerve 69
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 69
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 67
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 67
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 65
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 64
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 61
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 60
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 59
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 58
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 58
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 57
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 54
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 53
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 52
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 52
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 51
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 51
Quality of life and psychological impact in patients with atopic dermatitis 50
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 49
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 49
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 49
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 48
Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor 48
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 48
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 48
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 47
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 47
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 46
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 45
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients 44
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 42
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 42
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 42
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 42
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 41
Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab 40
Totale 16.229
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.471
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.402 0 0 0 0 0 426 347 303 61 161 75 29
2021/2022861 46 69 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20261.777 293 158 578 254 359 135 0 0 0 0 0 0
Totale 16.689